The National Alliance of Advocates
for Buprenorphine Treatment

Buprenorphine (Suboxone^®, Subutex^®3, Zubsolv^™4, Probuphine^®5) is an opioid medication used to treat opioid addiction in the privacy of a physician's office.¹ Buprenorphine can be dispensed for take-home use, by prescription.¹ This, in addition to the pharmacological and safety profile of buprenorphine, makes it an attractive treatment for patients addicted to opioids.²

This page was last modified on : 10/20/2011

Educate the public about the disease of opioid addiction and the buprenorphine treatment option.
Help reduce the stigma and discrimination associated with patients with addiction disorders.
Serve as a conduit connecting patients in need of treatment to buprenorphine treatment providers.

U.S. Food and Drug Administration, FDA Talk Paper, T0238, October 8, 2002, Subutex and Suboxone approved to treat opiate dependence.
Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, Md: Substance Abuse and Mental Health Services Administration, 2004.
Subutex Discontinued in the US market in late 2011.
Currently pending FDA approval. Expected approval in July 2013. see buprenorphine pipeline graphic
Rejected by FDA 4/30/2013 - Future Unknown - Probuphine denied by FDA